Molecular surveillance of aggressive large B-cell lymphoma using circulating tumor DNA duplexes
Blood tests tracking tumor DNA during lymphoma treatment offer doctors real-time insight into whether therapy is working.
This PubMed-indexed phase ii clinical trial examined Molecular surveillance of aggressive large B-cell lymphoma using circulating tumor DNA duplexes. The abstract reports that overall, we demonstrate that ctDNA monitoring using an ultrasensitive technique provides a dynamic molecular tool to guide clinical decision-making during therapy and follow-up in patients with LBCL.
What the study was
- Study design
- Phase II clinical trial
- Population
- Molecular surveillance of aggressive large B-cell lymphoma using circulating tumor DNA duplexes.
- Category
- Other
- Maturity
- Validated
- Journal
- Haematologica
Why it surfaced
Phase II clinical trial with an abstract-supported finding relevant to Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma); scored conservatively because only the PubMed abstract was reviewed.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.